AbbVie stock surged early Friday after beating fourth-quarter expectations, largely on the back of its immunology drugs.
This pharma stock has made strong gains over the past 12 months thanks to its strong earnings. Now it is testing a fresh buy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback